News Sentiment

NVNO sentiment intelligence

enVVeno Medical Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 11.36 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+2.3% over one week, +13.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

EnVVeno Medical : Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction 2.3% Price confirming higher
Trend fit Trend inactive 13.6% over four weeks
Fair value -89.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 44
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 16
TradingView 10
Stock Titan 9
ACCESS Newswire 5
StockStory 2
marketscreener.com 1
富途牛牛 1
Investing.com Nigeria 1

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 22
Regulatory and legal 6
Deals and strategy 3
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
Stock Titan Direct company coverage

[144] enVVeno Medical Corp SEC Filing

This article details an SEC Form 144 filing by enVVeno Medical Corp (NVNO) on June 11, 2026. The filing indicates a proposed sale of 140 shares of common stock, acquired on December 31, 2024, through an open market purchase, with an aggregate market value of $1443.00. The transac

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 15:39
Source
Stock Titan
PhillyBurbs Direct company coverage

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

enVVeno Medical Corporation announced its financial results for the full year 2025, reporting a net loss of $19.5 million and $28.2 million in cash and investments. The company accelerated the development of its enVVe® System, a less invasive transcatheter replacement venous valv

Tone
Positive 70/100
Event
Earnings
Published
04 Jun 2026 05:40
Source
PhillyBurbs
ACCESS Newswire Direct company coverage

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

enVVeno Medical (NASDAQ:NVNO) announced that CEO Robert Berman will participate in a Virtual Investor Closing Bell event on June 9, 2026, at 4:00 PM ET. He will discuss the recent FDA IDE approval for the enVVe® System, a non-surgical replacement venous valve, and engage in a liv

Tone
Positive 72/100
Event
Regulatory and legal
Published
02 Jun 2026 13:38
Source
ACCESS Newswire
Finviz Direct company coverage

NVNO - enVVeno Medical Corp Stock Price and Quote

This article provides a detailed stock price, quote, and company overview for enVVeno Medical Corp (NVNO). It includes financial metrics, stock performance data, and a chronological list of recent news and press releases related to the company's developments, FDA approvals, and f

Tone
Neutral 50/100
Event
Market update
Published
01 Jun 2026 16:10
Source
Finviz
BioSpace Direct company coverage

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

enVVeno Medical reported its first-quarter 2026 financial results, ending the period with approximately $25 million in cash and investments, which is expected to fund operations into Q3 2027. The company highlighted receiving FDA IDE approval for its TAVVE U.S. Pivotal Study for

Tone
Positive 71/100
Event
Earnings
Published
26 May 2026 01:11
Source
BioSpace
Stock Titan Direct company coverage

Perceptive entities disclose 9.99% stake in enVVeno (NASDAQ: NVNO)

Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have filed a Schedule 13G/A, disclosing a beneficial ownership of 9.99% in enVVeno Medical Corporation (NASDAQ: NVNO). This stake, based on 667,669 outstanding shares as of May 1, 2026, is constra

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 19:40
Source
Stock Titan
Stock Titan Direct company coverage

Kingdon group holds 36,166 shares in enVVeno (NASDAQ: NVNO)

Kingdon-affiliated parties have disclosed beneficial ownership of 36,166 shares in enVVeno Medical Corp (NASDAQ: NVNO), amounting to a 5.5% stake in the company's common stock. This information was reported through an amended Schedule 13G/A filing with the SEC, indicating shared

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 17:40
Source
Stock Titan
ACCESS Newswire Direct company coverage

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

enVVeno Medical announced that CEO Robert Berman discussed the company's recent FDA IDE approval for a US pivotal study of a non-surgical replacement venous valve during a Virtual Investor "What This Means" segment. This approval is a significant step towards developing the first

Tone
Positive 72/100
Event
Regulatory and legal
Published
12 May 2026 13:10
Source
ACCESS Newswire
Zacks Investment Research Direct company coverage

Should I buy enVVeno Medical (NVNO)

Tone
Positive 66/100
Event
Market update
Published
25 Aug 2025 07:00
Source
Zacks Investment Research